Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

被引：0
|
作者：
Xu, Binghe [1 ]
Li, Qiao [1 ]
Zhang, Qingyuan [2 ]
Zhang, Yue [2 ]
Ouyang, Quchang [3 ]
Zhang, Yang [4 ]
Liu, Qiang [5 ]
Sun, Tao [6 ]
Xu, June [7 ]
Yang, Jing [7 ]
Yang, Yue [7 ]
Luo, Xin [7 ]
Kong, Paul [7 ]
Xu, Ting [7 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Hunan Canc Hosp, Changsha, Peoples R China
[4] Liaocheng Peoples Hosp, Liaocheng, Shandong, Peoples R China
[5] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[6] Liaoning Canc Hosp, Dalian, Peoples R China
[7] Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1660
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy, Safety, and Tolerability of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC):Final results of the Phase II trial
    Li, Qiao
    Zhang, Qingyuan
    Zhang, Yue
    Ouyang, Quchang
    Liu, Qiang
    Sun, Tao
    Ye, Feng
    Zhang, Baochun
    Xu, Ting
    Xia, Summer
    Zhang, Karl
    Zhang, Bangyong
    Xu, Binghe
    CANCER RESEARCH, 2023, 83 (05)
  • [2] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
    Li, Qiao
    Liu, Jiaxuan
    Zhang, Qingyuan
    Ouyang, Quchang
    Zhang, Yang
    Liu, Qiang
    Sun, Tao
    Ye, Feng
    Zhang, Baochun
    Xia, Summer
    Zhang, Bangyong
    Xu, Binghe
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [3] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
    Qiao Li
    Jiaxuan Liu
    Qingyuan Zhang
    Quchang Ouyang
    Yang Zhang
    Qiang Liu
    Tao Sun
    Feng Ye
    Baochun Zhang
    Summer Xia
    Bangyong Zhang
    Binghe Xu
    Nature Communications, 15
  • [4] Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial
    Liu, Jieqiong
    Song, Chuangui
    Wang, Xiangcai
    Ni, Mingli
    Wang, Xujuan
    Chen, Lei
    Yang, Hongwei
    Zhao, Rusen
    Xu, Ting
    Shen, Lin
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Preliminary Safety, Efficacy Results of KN046 (Bispecific Anti-PD-L1/CTLA4) in Subjects With Rare Thoracic Tumors
    Richardson, G.
    Kichenadasse, G.
    Ganju, V.
    Xu, J.
    Van, H.
    Kong, P.
    Yang, F.
    Wei, Y.
    Lu, Y.
    Guo, K.
    Donato, L.
    Xu, T.
    Coward, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S154 - S155
  • [6] PRELIMINARY SAFETY, TOLERABILITY AND EFFICACY RESULTS OF KN026 (A HER2-TARGETED BISPECIFIC ANTIBODY) IN COMBINATION WITH KN046 (AN ANTI-PD-L1/CTLA-4 BISPECIFIC ANTIBODY) IN PATIENTS (PTS) WITH HER2 ABERRATED SOLID TUMORS
    Gong, Jifang
    Dong, Zhi
    Liu, Dan
    Xu, June
    Yang, Jing
    Yang, Yue
    Qi, Yakun
    Men, Jie
    Kong, Paul
    Xu, Ting
    Shen, Lin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A207 - A207
  • [7] KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Preliminary efficacy and safety results of a prospective phase II trial
    Xing, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S822 - S822
  • [8] Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors
    Gong, J.
    Shen, L.
    Luo, S.
    Dong, Z.
    Liu, D.
    An, S.
    Xu, J.
    Yang, J.
    Qi, Y.
    Men, J.
    Kong, L.
    Yang, Y.
    Xu, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1042 - S1042
  • [9] The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
    Xu, Da
    Wang, Hongwei
    Bao, Quan
    Jin, Kemin
    Liu, Ming
    Liu, Wei
    Yan, Xiaoluan
    Wang, Lijun
    Zhang, Yanqiao
    Wang, Guangyu
    Ma, Yue
    Ma, Zhigang
    Zhang, Chunhui
    Tang, Jiebing
    Wang, Sha
    Pang, Jiaohui
    Xu, Ting
    Wang, Kun
    Xing, Baocai
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [10] A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.
    Xing, Baocai
    Da, Xu
    Zhang, Yanqiao
    Ma, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345